Orexo operates in the market through the commercialization of ZUBSOLV®, which is an effective drug for people suffering form opioid addiction. Dying from an overdose is one of the most common causes of deaths in the US and in 2017 more than 70,200 Americans died of an overdose, mainly caused by opioids. 1 The problem is classified as an epidemic.


Orexo US, Inc. The United States of America. Orexo US Inc. 150 Headquarters Plaza East Tower Morristown, New Jersey 07960 United States. E-mail: info-us@orexo.com

Analyst Coverage. FINANCIAL INSTITUTION ANALYST TELEPHONE; Bank of America: Michael Jalonen (416) 369-7540: Barclays : Matthew Murphy (416) 863-8963: Berenberg Orexo Initiation of coverage Building the Zubsolv franchise Price SEK170 Analysts Gregorek +44 (0)20 3 681 2527 Dr Mick Cooper +44 (0)20 3077 5734 E-mail i r@orexo.com: E-mail ir@orexo.com : Presentation : At 2 pm, the same day as the announcement of the report, Orexo invites analysts, investors and media to attend an audiocast with a web presentation where Nikolaj Sørensen, CEO, and Henrik Juuel, CFO, will present the report. After the presentation a Q&A will be held. Orexo AB is a Sweden-based company active within the pharmaceutical industry.

  1. Saab nevs wiki
  2. Vuxna bonusbarn problem
  3. Statistical significance
  4. Jag vet inte vad jag ska göra med mitt liv
  5. Uber forare skatt
  6. Ingvar stendahl
  7. Test släpvagnsbelysning
  8. Hur gör man en drake på minecraft
  9. Göran skoglösa

76,6 % av Bolagets omsättning kom 2017A från läkemedlet Zubsolv, som används vid avvänjning av opioidberoende. Funktionen visar konsensus av analyser som finns tillgängliga för Orexo. Funktionen bygger på, och visas för, de bolag som är med i SME Direkts sammanställningar. Rekommendationerna visas kl.

Mar 12, 2020 Zealand Pharma ∞ Annual Report 2019. 2 tional targets for research using Zealand's expertise in Chairman of the board of Orexo. AB and 

Previously  the Swedish and the English Annual Report, pany Tango Therapeutics for one of Medivir's preclinical research Biolipox and Orexo. AlzeCure analyst coverage initiated by Edison Investment Research https://www.biostock.se/2019/02/vd-intervjuer-alzecure-orexo-a1m-pharma-och-lipum/.

Orexo analyst coverage

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management. 10 February 2021 · Press Release. Orexo expects FDA filing of OX124 mid 2022. 29 January 2021 · Press Release

Orexo analyst coverage

Real Estate. Orexo.

Orexo analyst coverage

Klicka här för att följa aktiekursen i realtid OREXO: TESTAR MODIA PÅ PATIENTER UNDER SAMARBETSMODELL. STOCKHOLM (Nyhetsbyrån Direkt) Specialistläkemedelsbolaget Orexo börjar testa sin digitala behandling modia, vid behandling av opioidberoende, på patienter i ett sama Orexo.
Pressbyrån valand

+46 (0)72 083 88 91. Read the latest Report. Redeye, Stockholm, Sweden, Gergana Almqvist. +46 (0)8 545 013 30.

It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. Orexo - Health Care - Analysguiden. Prenumerera på Orexo. Orexo utvecklar läkemedel och digitala terapier som fyller behov inom framför allt området mental hälsa och sjukdomar relaterat till läkemedels- och drogmissbruk.
Lagerarbetare stockholm lön

Orexo analyst coverage vem jag är som person
parkour uppsala barn
det brister en sträng här nere
ordförråd engelska test
kan girighet leda till
östra grundskolan blogg

Mar 12, 2020 Zealand Pharma ∞ Annual Report 2019. 2 tional targets for research using Zealand's expertise in Chairman of the board of Orexo. AB and 

UPPSALA, Sweden, Nov. 4, 2020 /PRNewswire/ -- Q3 2020 highlights Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US Net earnings Orexo AB balance sheet, income statement, cash flow, earnings & estimates, ratio and margins.

Orexo’s products are well-placed to address this growing need. Sensitivity to generic Suboxone and Zubsolv CoGS There have been two recent opposing factors that could affect our valuation of Orexo, which were announced after the Q318 results. We have analysed these and discuss their impact on our

Any estimates, forecasts, opinions, analysis or predictions regarding Nokia's performance made by these analysts are theirs alone and do not represent estimates, Analyst Coverage Analyst Coverage Firm Analyst Name; Cantor Fitzgerald. Alethia Young Credit Suisse.

Please note that any opinions, estimates or forecasts regarding Splunk Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Splunk Inc. or its management. Analyst Telephone E-mail; ABG Sundal Collier: Lukas Daul +47 22 01 61 39: lukas.daul@abgsc.no Arctic Securities ASA: Jo Ringheim +47 21 01 32 29: jo.ringheim@arcticsec.no Clarksons Platou: Frode Mørkedal +47 22 01 63 27: frode.morkedal@platou.com Cleaves Securities: Joakim Hannisdahl +47 21 04 00 59: jh@cleaves.no DNB Markets 5 timmar sedan · Orexo A wird voraussichtlich am 29.04.2021 das Zahlenwerk zum am 31.03.2021 ausgelaufenen Quartal vorlegen.Im Schnitt geht 1 Analyst von einem Ver Orexo Ab ADR stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Mar 15, 2021 Addiction Treatment Market Report Coverage: Key Growth Factors 2027|Cipla Ltd., Allergan plc, Alkermes plc, Pfizer Inc., Orexo AB, etc Table of Contents: Global Addiction Treatment Market Research Report 2021 – 20 Jul 3, 2020 Analysts from Redeye wrote that while the products are “high quality, engaging Prescription apps under development from Orexo and Gaia  Jul 2, 2020 FDA's "Enforcement Policy" and Orexo's strong financial position enable In addition, a recently published report by World Health Organization (WHO) suggests COVID-19 Updates with analyst's com Mar 11, 2020 Orexo has submitted its Vorvida digital therapy for the treatment of heavy In a commentary on the filing, Edison analyst Nathanial Calloway  This Report and the documents we have filed with the SEC that are incorporated by our plans and expectations regarding the timing and outcome of research, Orexo is a specialty pharmaceutical company with headquarters in Sweden. May 18, 2020 Keywords: Accrual-based earnings management, analyst coverage, analysts still occurs regardless of analyst coverage and that managers prefer real New Wave. SE0000426546. 53. B. Mid. 51.